I received my PhD from the University of Paris-Diderot in collaboration with the biotech company Cellectis. During my PhD, I participated to the development of gene editing tools such as Meganuclease or TALEN in primary human cells and notably identified genomic location for safe integration of therapeutic genes. In 2014, I joined Michel Sadelain’s lab at the MSKCC and used CRISPR/Cas9 to engineer CAR T cells. I showed how targeting CAR transgene into specific loci enhance T cell efficacy, advance CAR immuno-biology and facilitate T cell manufacturing.
